Related Experiment Video

Updated: Sep 2, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a

Jonathan Afari1, Tanya M Spektor2, Carley Turner2

  • 1Berenson Cancer Center, West Hollywood, CA; Sackler School of Medicine, Tel Aviv, Israel.

Experimental Hematology
|August 7, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Related Experiment Videos

Last Updated: Sep 2, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

Articles linked to this work by shared authors, journal, and citation graph.

Outcomes and recovery timelines of 249 patients with Parsonage-Turner syndrome from a major tertiary care center.

JSES international·2026

Genetic risk and immune dysregulation of classic Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma: a multicentric study.

medRxiv : the preprint server for health sciences·2026

Diagnostic Yield of Serial PR Interval Screening for Fetal Heart Block in Anti-SSA/SSB Pregnancies.

Prenatal diagnosis·2026

Treatment with Daratumumab in Combination with Glucocorticosteroids as First-Line Treatment Achieves a Complete Remission for a Patient with Multiple Myeloma and Resolves Neutropenia: A Case Report.

Case reports in oncology·2026

Single Center Retrospective Comparison of Post-Transplant Cyclophosphamide and Standard Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Transplantation.

Transplantation proceedings·2026

A catecholamine-independent pathway controlling adaptive adipocyte lipolysis.

Nature metabolism·2026

Effect of the dominant-negative Ikaros isoform 6 (Ik6) on cell function and drug sensitivity in Ph-positive acute lymphoblastic leukemia cell lines.

Experimental hematology·2026

Haematopoietic stem cell fitness mechanisms.

Experimental hematology·2026

Midbody inheritance predicts re-entry into quiescence, but not lineage potential, in mouse hematopoietic stem cells.

Experimental hematology·2026

Mast cell-derived histamine negatively regulates hematopoiesis.

Experimental hematology·2026

Phenotypic remodeling and functional impairment of circulating neutrophils are associated with infection-related mortality in acute myeloid leukemia.

Experimental hematology·2026

Evolution in the cryopreservation of hematopoietic stem cells.

Experimental hematology·2026

Trial designs for assessing induction, maintenance and other treatment effects on a continuous endpoint.

Journal of biopharmaceutical statistics·2026

Direct Oral Anticoagulant Plus Single Versus Dual Antiplatelet Therapy After Carotid Artery Stenting: A Multicenter Propensity-Matched Cohort Study.

Neurosurgery·2026

First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study.

Future oncology (London, England)·2026

Cannabis Assessment in Oncology Patients - Evaluation Survey: Understanding Usage Patterns in a Rural Radiation Cohort in Kentucky.

The oncologist·2026

Spontaneous Regression of Vitreoretinal Lymphoma Lesions: Case Series and Literature Review.

Ocular immunology and inflammation·2026

Blockade of the PD-1 / PD-L1 Axis Exacerbates Chronic Nocardia Brasiliensis Infection by Disrupting Bacterial Immune Containment in BALB/c Mice.

Immunological investigations·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us